Get the Stockscreener App
13.68
10.32%
-1.72
Omeros Corporation stock is traded at $13.68, with a volume of 4.48M.
It is down -10.32% in the last 24 hours and up +27.28% over the past month.
Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.
See More
Previous Close:
$15.40
Open:
$15.09
24h Volume:
4.48M
Relative Volume:
1.05
Market Cap:
$970.98M
Revenue:
-
Net Income/Loss:
$-117.81M
P/E Ratio:
-7.2766
EPS:
-1.88
Net Cash Flow:
$74.30M
1W Performance:
-18.57%
1M Performance:
+27.28%
6M Performance:
+331.56%
1Y Performance:
+27.40%
1-Day Range:
$13.57
$15.12
1-Week Range:
$13.57
$17.63
52-Week Range:
$2.95
$17.65
Omeros Corporation Stock (OMER) Company Profile
Name
Omeros Corporation
Sector
Industry
Phone
206-676-5000
Address
201 ELLIOTT AVENUE WEST, SEATTLE, WA
Compare OMER with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OMER
Omeros Corporation
|
13.70 | 1.09B | 0 | -117.81M | 74.30M | -1.88 |
|
VRTX
Vertex Pharmaceuticals Inc
|
467.85 | 113.87B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
773.46 | 80.22B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
405.59 | 52.56B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
801.70 | 49.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
174.74 | 37.37B | 447.02M | -1.18B | -906.14M | -6.1812 |
Omeros Corporation Stock (OMER) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-10-25 | Initiated | H.C. Wainwright | Buy |
| Dec-23-24 | Initiated | D. Boral Capital | Buy |
| Nov-14-24 | Initiated | Rodman & Renshaw | Buy |
| Dec-08-22 | Downgrade | UBS | Buy → Neutral |
| Nov-08-22 | Downgrade | BofA Securities | Neutral → Underperform |
| Jun-08-22 | Downgrade | BofA Securities | Buy → Neutral |
| Oct-08-21 | Downgrade | JP Morgan | Neutral → Underweight |
| Oct-01-21 | Downgrade | Maxim Group | Buy → Hold |
| Oct-01-21 | Downgrade | Wedbush | Neutral → Underperform |
| Sep-27-21 | Initiated | JP Morgan | Neutral |
| Feb-01-21 | Initiated | UBS | Buy |
| Oct-20-20 | Initiated | BofA Securities | Buy |
| Aug-21-20 | Reiterated | H.C. Wainwright | Buy |
| Aug-14-20 | Reiterated | Maxim Group | Buy |
| May-06-19 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-12-18 | Initiated | Seaport Global Securities | Buy |
| Mar-23-18 | Downgrade | Wedbush | Outperform → Neutral |
| Mar-05-18 | Downgrade | Needham | Buy → Hold |
| Nov-08-17 | Initiated | H.C. Wainwright | Buy |
| May-11-17 | Downgrade | Cantor Fitzgerald | Buy → Neutral |
| Mar-17-17 | Reiterated | Maxim Group | Buy |
| Mar-17-17 | Reiterated | Needham | Buy |
| Nov-16-16 | Reiterated | Wedbush | Outperform |
| Nov-10-16 | Reiterated | Needham | Buy |
| Aug-10-16 | Reiterated | Maxim Group | Buy |
| Jun-03-16 | Initiated | Cantor Fitzgerald | Buy |
| Mar-02-16 | Reiterated | Needham | Buy |
| Feb-29-16 | Reiterated | Wedbush | Outperform |
| Nov-11-15 | Reiterated | Needham | Buy |
| Aug-18-15 | Reiterated | WBB Securities | Strong Buy |
| Aug-10-15 | Initiated | ROTH Capital | Buy |
View All
Omeros Corporation Stock (OMER) Latest News
Omeros (NASDAQ:OMER) Trading Down 6%Should You Sell? - MarketBeat
Will FDA Approval of YARTEMLEA in TA-TMA Redefine Omeros' (OMER) Commercial Trajectory? - simplywall.st
Omeros (NASDAQ:OMER) Sets New 12-Month HighStill a Buy? - MarketBeat
Omeros Corporation (NASDAQ:OMER) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Omeros stock jumps premarket after FDA approves first drug for rare transplant complication — retail sees big upside - MSN
Will Omeros Corporation stock deliver better than expected guidanceGrowth Stock Opportunities & Ride the Wave of Market-Beating Growth - bollywoodhelpline.com
Omeros (NASDAQ:OMER) Trading Up 4.6%Here's Why - MarketBeat
Best Pharmaceutical Stocks To Watch TodayDecember 24th - MarketBeat
Retail’s Christmas Eve watchlist: Omeros, Nike, Citi, Dynavax and Agios spark most market chatter - MSN
Commit To Buy Omeros At $10, Earn 26.6% Annualized Using Options - Nasdaq
Omeros Gets FDA Approval for YARTEMLEA as First Therapy for TA-TMA - Yahoo Finance
Omeros Corp Stock Soars A Whopping 136% Pre-Market After Novo Nordisk Agrees To Buy Its Drug Candidate For Blood Disorder - MSN
Omeros Corp Announces FDA Approval of YARTEMLEA for TA-TMA - TradingView — Track All Markets
Omeros (NASDAQ: OMER) secures FDA nod for YARTEMLEA in TA-TMA - Stock Titan
Omeros: Why The Novo Nordisk Deal Is More Important Than FDA Approval (Rating Upgrade) - Seeking Alpha
Omeros to resume trading at 9:50 AM ET - MSN
D Boral Capital notes Omeros’ YARTEMLEA FDA win, maintains buy rating - MSN
Why Omeros stock skyrocketed today - MSN
Omeros Announces New Date for YARTEMLEA® Approval Conference Call - Caledonian Record
Omeros stock garners high retail attention ahead of FDA verdict for life-saving drug - MSN
Omeros scores its 1st FDA nod as stem cell transplant drug Yartemlea approved - Fierce Pharma
Omeros (NASDAQ:OMER) Sees Large Volume IncreaseStill a Buy? - MarketBeat
Biohaven, Omeros And Other Big Stocks Moving Lower In Friday's Pre-Market Session - Benzinga
Omeros rockets as FDA approves Yartemlea - The Pharma Letter
Analysts Are Neutral on Top Healthcare Stocks: Biohaven Ltd. (BHVN), Omeros (OMER) - The Globe and Mail
WBB Securities Reaffirms Their Buy Rating on Omeros (OMER) - The Globe and Mail
Omeros (OMER): Revisiting Valuation After a Powerful Multi‑Year Share Price Repricing - Yahoo Finance
Omeros (OMER) Stock Surges After FDA Approval of Yartemlea: Latest News, Analyst Forecasts, and 2026 Outlook - ts2.tech
Omeros wins FDA nod for transplant therapy - MSN
Omeros (NASDAQ:OMER) Hits New 12-Month HighTime to Buy? - MarketBeat
Omeros (OMER) Valuation After FDA Approval of First TA-TMA Therapy Yartemlea and Shift to Commercial Stage - simplywall.st
Corient Private Wealth LLC Reduces Stock Holdings in Omeros Corporation $OMER - MarketBeat
Why Omeros (OMER) Is Up 74.0% After First-In-Class TA-TMA Drug Wins FDA Approval - Yahoo Finance
Nike, Omeros Corporation, Micron Technology, Intel And Dynavax Technologies: Why These 5 Stocks Are On Investors' Radars Today - Sahm
NKE, OMER, MU, INTC, DVAX: 5 Trending Stocks TodayNike (NYSE:NKE) - Benzinga
Omeros Stock Jumps Premarket After FDA Approves First Drug For Rare Transplant Complication — Retail Sees Big Upside - Stocktwits
Why Omeros Stock Skyrocketed Today - AOL.com
Why Omeros Stock Skyrocketed Today - The Motley Fool
Omeros (OMER) Stock Surges After Hours on Dec. 24, 2025 After FDA Approves Yartemlea — What to Know Before the Next Market Open - ts2.tech
US FDA approves Omeros' drug to treat dangerous transplant complication - Reuters
Retail’s Christmas Eve Watchlist: Omeros, Nike, Citi, Dynavax And Agios Spark Most Market Chatter - Asianet Newsable
Omeros: Stock Pops On Yartemlea Approval, Longer-Term Upside Likely (NASDAQ:OMER) - Seeking Alpha
FDA approves Omeros’ Yartemlea for stem cell patients - BioWorld MedTech
Omeros' Yartemlea lands FDA nod for often-fatal transplant complication - FirstWord Pharma
Stock Traders Buy High Volume of Call Options on Omeros (NASDAQ:OMER) - MarketBeat
Omeros' (OMER) "Buy" Rating Reiterated at D. Boral Capital - MarketBeat
OMER: Analyst Maintains 'Buy' Rating and $36 Price Target | OMER Stock News - GuruFocus
H.C. Wainwright Maintains Omeros(OMER.US) With Buy Rating, Maintains Target Price $20 - 富途牛牛
Omeros (NASDAQ:OMER) Trading Up 74.2%What's Next? - MarketBeat
Omeros (OMER) Secures FDA Approval for Breakthrough Treatment - GuruFocus
Why Is Omeros Stock Skyrocketing Wednesday?Omeros (NASDAQ:OMER) - Benzinga
Omeros Corporation Stock (OMER) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.45%
0.43%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):